Skip to main content
Premium Trial:

Request an Annual Quote

Tandem Labs Acquires Linden Technologies Unit PharmaKD

NEW YORK (GenomeWeb News) — Tandem Labs, a Salt Lake City-based bioanalytical and immunoanalytical testing firm, today announced that it has acquired PharmaKD, a subsidiary of Linden Technologies.
Through the acquisition, Tandem gets the rights to PharmaKD’s DMDiscovery drug metabolism technology for increasing the productivity of drug metabolite identification and quantitation, and MarkerScan, a biomarker discovery and screening process for identifying potential biomarkers.
Under the agreement, Tandem Labs will “retain key personnel, intellectual property portfolios, proprietary informatics, scientific instruments, and 7,000 square feet of operational space from PharmaKD,” the company said.
PharmaKD has been renamed Tandem Labs-New England and will offer metabolite profiling, identification, and quantitation; biomarker discovery and screening; protein-binding assays; and discovery bioanalytical support services, Tandem said.
Financial details of the transaction were undisclosed.

The Scan

Not Immediately Told

The US National Institutes of Health tells lawmakers that one of its grantees did not immediately report that it had developed a more infectious coronavirus, Science says.

Seems Effective in Kids

The Associated Press reports that the Pfizer-BioNTech SARS-CoV-2 vaccine for children appears to be highly effective at preventing symptomatic disease.

Intelligence Warning on Bioeconomy Threats

US intelligence warns over China's focus on technologies and data related to the bioeconomy, the New York Times reports.

PLOS Papers on Campylobacteriosis Sources, Inherited Retinal Dystrophies, Liver Cancer Prognosis

In PLOS this week: approach to uncover source of Campylobacteriosis, genetic risk factors for inherited retinal dystrophies, and more.